Palo Alto, CANCT06161415Now EnrollingIRB Ready

Inflammation Clinical Trial in Palo Alto, CA

Access cutting-edge inflammation treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.

Sponsored by Quan Dong Nguyen

Quick Self-Assessment

See if you qualify for this Palo Alto location

Preparing your pre-screening questions…

Expert Care in Palo Alto

Access inflammation specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related inflammation treatment provided free

Apply for This Palo Alto Location

Check if you qualify for this inflammation clinical trial in Palo Alto, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Palo Alto

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Palo Alto site if eligible
  4. 4Begin participation

About This Inflammation Study in Palo Alto

The LION Study is a prospective, single-center phase 1 clinical trial to evaluate the safety, tolerability, and distribution of Laquinimod administered as topical eye drops for two weeks in human participants.

Sponsor: Quan Dong Nguyen

Who Can Participate

Inclusion Criteria

Age 18 years or older
Participants who are capable and willing to provide informed consent and follow study instructions.
Participants who are scheduled to undergo pars plana vitrectomy (PPV).
Participants with intraocular pressure (IOP) ≥ 5 mmHg and ≤22 mmHg in study eye
Women who are not pregnant or lactating, are post-menopausal or have undergone a sterilization procedure.

Exclusion Criteria

Participants with active periocular or ocular infectious disease (e.g., blepharitis, scleritis, or conjunctivitis, keratitis or endophthalmitis).
Participants with active infectious uveitis
Participants with a history of prior intraocular or extraocular surgery within 90 days of study enrollment
Participant with a history of intravitreal steroids administered to the study eye within 90 days of enrollment.
Participants with a history of intravitreal injection of VEGF inhibitors within 30 days of enrollment
Use of any topical cyclosporine or corticosteroid or other specified (i.e. calcineurin inhibitors) ophthalmic medication in the study eye for any reason within 14 days of enrollment and before the surgery
Use of medication consisting of a strong or moderate inhibitor of CYP3A4 within 2 weeks of Baseline visit (and during the study).
Use of medication consisting of a strong inducer of CYP3A4 within 2 weeks of Baseline visit (and during the study)
Mild, moderate, or severe hepatic impairment (any of Child-Pugh Score A, B, and C)
Moderate or severe renal impairment (GFR ≤60 mL/min)
History of HIV disease or other immunodeficiency disorder
History of acute hepatitis A (IgM positive), hepatitis B, or hepatitis C
History of organ or bone marrow transplant
Presence of malignancy under active treatment
Any other acute or chronic medical condition that would, in the judgment of the study investigators, reasonably preclude participation in the clinical study
Already enrolled in a clinical trial.
Any condition that would prevent the investigator from acquiring images of the eye as required per protocol

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Palo Alto?

Yes, this clinical trial (NCT06161415) has an active research site in Palo Alto, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Inflammation Treatment Options in Palo Alto, CA

If you're searching for inflammation treatment options in Palo Alto, CA, this clinical trial (NCT06161415) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced inflammation specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all inflammation clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Palo Alto, CA

See all multiple myeloma clinical trials recruiting in Palo Alto — not just this study.

Browse Multiple Myeloma Trials in Palo Alto →

Browse More Trials by Condition

Multiple Myeloma TrialsFollicular Lymphoma TrialsMyocarditis TrialsVasculitis TrialsMyositis TrialsInflammatory Bowel Disease TrialsAtopic Dermatitis TrialsPancreatitis TrialsAll Conditions →

Ready to Join in Palo Alto?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Palo Alto, CA